Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEPOTASTINE BESILATE vs ACULAR PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.
Allergic conjunctivitis (FDA approved),Allergic rhinitis (off-label),Urticaria (off-label)
FDA-approved: Treatment of ocular inflammation and pain following cataract surgery and corneal refractive surgery.,Off-label: Relief of seasonal allergic conjunctivitis symptoms, management of cystoid macular edema, and treatment of postoperative inflammation in other ocular procedures.
2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.
1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.
Terminal elimination half-life is approximately 9-10 hours in healthy adults, allowing twice-daily dosing for allergic conjunctivitis.
Terminal elimination half-life is approximately 5-6 hours in adults, but can be prolonged in elderly patients (up to 8-9 hours) and in patients with renal impairment (up to 13-19 hours).
Primarily metabolized via glucuronidation (UGT1A9, UGT2B7) and oxidation (CYP3A4 minor pathway).
Ketorolac undergoes hepatic metabolism via hydroxylation and conjugation (glucuronidation) to inactive metabolites. It is primarily metabolized by CYP2D6 and CYP3A4 isoenzymes, with renal excretion of metabolites and unchanged drug.
Primarily renal excretion as unchanged drug (~75-80% of dose) with minor fecal elimination (~10-15%).
Primarily renal excretion of metabolites and unchanged drug; approximately 80% of a dose is excreted in urine as ketorolac and its hydroxy metabolites, with about 6% excreted in feces.
Approximately 55-60% bound to human plasma proteins, primarily albumin.
99% bound to plasma proteins, primarily albumin.
Following oral administration, Vd is 1.4-1.8 L/kg, indicating extensive tissue distribution. Not applicable for ophthalmic use.
0.15-0.25 L/kg after oral administration; for ophthalmic use, systemic absorption is minimal, so Vd is not clinically meaningful.
Oral bioavailability is <1% due to extensive first-pass metabolism. Ophthalmic: Systemic absorption negligible (<0.5%).
Ophthalmic administration: Systemic bioavailability is approximately 0.5-1% after ocular instillation due to low corneal penetration and rapid clearance; oral bioavailability is 100%.
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dosage adjustment required for renal impairment. Drug is minimally absorbed systemically.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dosage adjustment required for hepatic impairment. Drug is minimally absorbed systemically.
≥2 years: same as adult dose (1 drop in each affected eye twice daily).
Children ≥3 years: 1 drop into affected eye(s) four times daily. Safety and efficacy in children <3 years not established.
No dose adjustment required; same as adult dosing.
No specific dosage adjustment required. Use same dose as adults; monitor for tolerability.
None.
NSAIDs may increase the risk of serious cardiovascular events (e.g., myocardial infarction, stroke) and gastrointestinal events (e.g., bleeding, ulceration, perforation). However, due to low systemic absorption with ophthalmic use, this boxed warning is less clinically relevant but still applies.
May cause severe hypersensitivity reactions (angioedema, bronchospasm).,Avoid use in patients with known hypersensitivity to bepotastine.,Ophthalmic use: do not wear contact lenses during treatment; may cause transient burning/stinging.,Systemic use: caution in patients with renal impairment (dose adjustment required).,Avoid concurrent use with CNS depressants due to additive sedative effects.
Use with caution in patients with compromised ocular surface, history of herpes simplex keratitis, bleeding tendencies, or those on anticoagulants. Prolonged use may delay wound healing. Monitor for signs of corneal epithelial breakdown or infection.
Hypersensitivity to bepotastine or any component of the formulation.,Severe renal impairment (Cr Cl <30 m L/min) for systemic use.
Hypersensitivity to ketorolac or any component of the formulation; patients with active ocular infection or advanced dry eye; history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.
No clinically significant food interactions reported with ophthalmic use.
No known food interactions. No dietary restrictions required.
Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human clinical dose) and 100 mg/kg/day in rabbits (approximately 200 times the human clinical dose), but there are no adequate and well-controlled studies in pregnant women. During the first trimester, the risk is unknown; during the second and third trimesters, potential risks to the fetus cannot be excluded.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to 1.5-3 times the human exposure. However, because NSAIDs can cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester, use is contraindicated after 30 weeks gestation. In first and second trimesters, use only if potential benefit justifies potential fetal risk.
It is not known whether bepotastine besilate is excreted in human milk. In rat studies, drug-related material was detected in milk following oral administration. Because many drugs are excreted in human milk, caution should be exercised when bepotastine besilate is administered to a nursing woman. The milk-to-plasma (M/P) ratio has not been established for humans. Breastfeeding is not recommended during treatment.
Ketorolac is excreted in human milk following oral administration. After a single intramuscular dose of 10 mg, the milk-to-plasma (M/P) ratio was 0.037. Low levels are expected in breastmilk; however, due to potential adverse effects of NSAIDs on neonates, caution is advised. Use is generally avoided in nursing mothers, especially with premature infants or those with thrombocytopenia or renal impairment.
No dose adjustments are recommended for pregnant women based on current pharmacokinetic data. However, systemic absorption after ophthalmic administration is minimal, and no pregnancy-specific pharmacokinetic studies have been conducted. Use caution and prescribe only if clearly needed.
No specific pharmacokinetic studies in pregnancy. Dosing should be at the lowest effective dose for the shortest duration. Avoid use after 30 weeks gestation. No adjustment for first or second trimester unless renal function changes.
Bepotastine besilate is a selective histamine H1 receptor antagonist used topically for allergic conjunctivitis. Avoid use with contact lenses; remove before instillation and wait at least 10 minutes before reinserting. Systemic absorption is minimal, but caution in patients with severe hepatic impairment. Onset of action is within 15 minutes, duration 8 hours. Do not touch dropper tip to eye or surrounding surfaces.
ACULAR (ketorolac tromethamine ophthalmic solution) is an NSAID for ocular use. Preservative-free formulation is indicated for single-use to avoid corneal toxicity. Apply with caution in patients with bleeding disorders or those on anticoagulants due to risk of ocular bleeding. Prolonged use may delay corneal healing. Monitor for signs of keratitis or conjunctival hyperemia.
Wash hands before use.,Tilt head back, pull lower eyelid down, and instill one drop in the affected eye(s) twice daily.,Do not touch the dropper tip to your eye or any surface.,Remove contact lenses before use and wait at least 10 minutes before reinserting.,Do not use if solution changes color or becomes cloudy.,Common side effects include mild eye irritation, bitter taste, or headache.,If you experience eye pain, vision changes, or redness, contact your doctor.
Use exactly as prescribed; do not touch the dropper tip to any surface to avoid contamination.,Each single-use vial is for one dose only; discard after use to prevent infection.,Remove contact lenses before instillation and wait 10 minutes before reinserting.,Do not drive or operate machinery if vision is blurry after application.,Report eye pain, increased redness, or vision changes to your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEPOTASTINE BESILATE vs ACULAR PRESERVATIVE FREE, answered by our medical review team.
BEPOTASTINE BESILATE is a Ophthalmic Antihistamine that works by Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.. ACULAR PRESERVATIVE FREE is a NSAID Ophthalmic that works by Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEPOTASTINE BESILATE and ACULAR PRESERVATIVE FREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEPOTASTINE BESILATE is: 2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.. The standard adult dose of ACULAR PRESERVATIVE FREE is: 1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEPOTASTINE BESILATE and ACULAR PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEPOTASTINE BESILATE is classified as Category C. Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human c. ACULAR PRESERVATIVE FREE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.